TL;DR: The Centers for Medicare & Medicaid Services (CMS) modified NCD 210 governing Medicare home health nursing visits for patients requiring subcutaneous heparin injections, effective March 7, 2026. If your agency bills for home health services involving anticoagulation therapy, this policy sets the specific coverage criteria, visit limits, and documentation requirements your team needs to get right before submitting claims.
CMS's NCD 210 is the National Coverage Determination governing Medicare reimbursement for home health nurses' visits to patients who require low-dose heparin injections — whether those visits are for patient teaching or for the nurse to administer the injections directly. The policy does not list specific CPT or HCPCS codes, but the coverage criteria and duration limits are detailed enough that documentation gaps will trigger claim denial. Here's what your billing team needs to know.
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Home Health Nurses' Visits to Patients Requiring Heparin Injection |
| Policy Code | NCD 210 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium — High for home health agencies with obstetric or anticoagulation patient populations |
| Specialties Affected | Home Health, Obstetrics, Hematology, Internal Medicine, Vascular Surgery |
| Key Action | Audit your documentation practices for heparin injection visits against the specific indications, caregiver-ability criteria, and 6-month duration limits outlined in the modified NCD 210 before March 7, 2026. |
CMS Home Health Heparin Injection Coverage Criteria and Medical Necessity Requirements 2026
The coverage policy here is narrower than it might look at first pass. Medicare will reimburse home health nursing visits for subcutaneous low-dose heparin injections under two specific clinical scenarios — and only those two.
First: The patient is pregnant and requires anticoagulant therapy. Heparin is the drug of choice for anticoagulation during pregnancy, so this is a straightforward medical necessity argument as long as the patient meets homebound criteria and a physician has prescribed the treatment.
Second: The patient requires treatment for deep venous thrombosis, pulmonary emboli, or another condition requiring anticoagulation, and documentation justifies that the patient cannot tolerate warfarin. That phrase — "documentation justifies" — is where claims fall apart. Warfarin is the usual drug of choice for these conditions. If you're billing heparin visits for a non-pregnant DVT or PE patient, the chart must make a clear case for warfarin intolerance or sensitivity. "Patient preferred heparin" doesn't cut it.
The coverage policy covers two types of nursing visits: teaching visits and administration visits. Teaching visits — where the nurse instructs the patient or a caregiver to self-administer the injection — are reimbursable for "several visits." The policy doesn't specify an exact number, which means your medical director and documenting clinicians need to justify each visit as medically necessary given the patient's or caregiver's demonstrated learning progress.
Administration visits are a different calculation. If the patient or caregiver is unable to administer the injection, Medicare will reimburse daily nursing visits — seven days a week — for up to six months. That's a significant reimbursement commitment, and it comes with a hard documentation requirement: the patient's inability to self-administer must be documented, not assumed.
There's no prior authorization requirement specified in NCD 210, but that doesn't mean your MAC won't scrutinize these claims. Document as if prior auth were required.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Pregnant patient requiring anticoagulant therapy (homebound) | Covered | Not specified in policy | Nursing visits may extend beyond 6 months if reasonable and necessary; no extended-duration documentation required |
| Deep venous thrombosis requiring anticoagulation, warfarin intolerance documented | Covered | Not specified in policy | Must document warfarin sensitivity/intolerance; heparin not covered simply as patient preference |
| Pulmonary emboli requiring anticoagulation, warfarin intolerance documented | Covered | Not specified in policy | Same documentation standard as DVT; physician must justify heparin over warfarin |
| Other condition requiring long-term anticoagulation, warfarin intolerance documented | Covered | Not specified in policy | Physician must document specific reason heparin is substituted |
| Teaching visits (patient or caregiver learning self-injection) | Covered | Not specified in policy | "Several visits" — no exact number defined; each visit must be individually justified |
| Daily administration visits (patient/caregiver unable to self-inject) | Covered up to 6 months | Not specified in policy | 7 days/week covered; beyond 6 months requires physician justification and documentation |
| Administration visits beyond 6 months, non-pregnant patients | Covered only with physician justification | Not specified in policy | Prescribing physician must document medical necessity for extended treatment |
| Administration visits beyond 6 months, pregnant patients | Covered without extended-duration documentation | Not specified in policy | Standard homebound criteria still applies |
| Heparin use without documented warfarin intolerance (non-pregnant) | Not Covered | Not specified in policy | Warfarin is the drug of choice; heparin substitution requires documented clinical justification |
CMS Home Health Heparin Injection Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your active heparin injection cases against the two covered indications before March 7, 2026. Pull every open home health episode involving subcutaneous heparin. Confirm each one is either a pregnant patient with a physician order or a patient with documented warfarin intolerance for DVT, PE, or another anticoagulation-requiring condition. If you find cases that don't fit either bucket, flag them for your compliance officer immediately. |
| 2 | Verify and strengthen warfarin intolerance documentation in the medical record. For non-pregnant patients, the claim defense lives entirely in the chart. "Demonstrated warfarin sensitivity" needs to appear as a clinical finding — lab values, adverse reaction notes, or physician narrative — not just a checkbox on the order form. Work with your clinical team to establish a documentation template before the effective date. |
| 3 | Establish a 6-month tracking trigger for daily administration visits. Your billing system should flag cases approaching 180 days of daily nursing visits. At that point, you need documented physician justification to continue billing. This is a hard stop for non-pregnant patients — claims beyond six months without documented necessity will be denied. Build the workflow now, not when you're already at month five. |
| 4 | Document caregiver ability assessments at every teaching visit. The policy distinguishes between teaching visits and administration visits based on whether the patient or caregiver can self-administer. If you're billing for ongoing daily nursing visits because the patient can't self-inject, the record needs to show that assessment was made — and updated. A patient who could not self-inject at week two may be reassessable at week eight. Document progress, or document persistent inability. |
| 5 | Confirm homebound status is documented and current for every episode. NCD 210 coverage applies only to homebound patients. Homebound status has to be established and maintained in the clinical record throughout the episode. A denial based on failure to document homebound status on a technically compliant heparin claim is an expensive and avoidable problem. |
| 6 | Loop in your compliance officer if you have pregnant patients with long-running episodes. The pregnancy exception — where visits beyond six months don't require the extended-duration documentation that non-pregnant patients do — is a genuine carve-out, but it still requires current homebound status documentation. If your census includes high-risk obstetric patients on long-term anticoagulation, your compliance officer should review how those episodes are being documented and billed. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Home Health Heparin Injection Visits Under NCD 210
CMS's NCD 210 does not list specific CPT, HCPCS, or ICD-10 codes in the policy document. The coverage criteria are narrative and indication-based rather than code-driven.
Your home health billing team should apply the appropriate home health visit codes consistent with your MAC's billing guidelines and the Medicare Benefit Policy Manual, Chapter 7 — which NCD 210 cross-references directly. If you're uncertain which codes your MAC expects for teaching versus administration visits in this clinical context, contact your MAC directly or consult your billing consultant before the effective date. Do not assume code selection from previous billing patterns alone — MACs vary in how they expect these visits to be coded, and a modified NCD is a reasonable trigger for a coding review.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.